SCHEMBL9914896

SCHEMBL9914896

COCCOCC(=O)N1CCN(C(=O)C(=O)c2c[nH]c3c(-n4cnc(C)n4)ncc(OC)c23)CC1

nearest known ligand 0.69

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.69
CYP2C9 P11712 2/20 0.69
CYP2D6 P10635 2/20 0.69
CYP1A2 P05177 1/20 0.69
CYP2C8 P10632 1/20 0.69
CYP2B6 P20813 1/20 0.69
CYP2C19 P33261 1/20 0.69
KCNH2 Q12809 1/20 0.69
BTK Q06187 2/20 0.33
TTK P33981 1/20 0.32
EPHX2 P34913 1/20 0.30
TLR9 Q9NR96 1/20 0.30
TLR8 Q9NR97 1/20 0.30
TLR7 Q9NYK1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9914890 0.94 CYP2D6 (0.75) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8
SCHEMBL9914888 0.88 CYP3A4 (0.75) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8
SCHEMBL16440228 0.87 CYP3A4 (0.77) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8
SCHEMBL9914891 0.86 CYP3A4 (0.71) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8
SCHEMBL15164819 0.86 CYP3A4 (0.78) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8
SCHEMBL15164805 0.86 CYP3A4 (0.78) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8
SCHEMBL15273638 0.85 CYP3A4 (0.69) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8
SCHEMBL17771868 0.84 CYP2D6 (0.61) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8
SCHEMBL9914944 0.84 CYP3A4 (0.75) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8
SCHEMBL9914945 0.84 CYP3A4 (0.72) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2646439-B1 ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-05-25 EP disclosed
US-8912195-B2 Alkyl amides as HIV attachment inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-12-16 US disclosed
US-8912195-B2 Alkyl amides as HIV attachment inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-12-16 US disclosed
US-20130252968-A1 ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2013-09-26 US disclosed
US-20130252968-A1 ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2013-09-26 US disclosed
WO-2012075235-A1 ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252968-A1 ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS NAPA, ASNS, CD4 CYP3A4 164/4885CYP2C9 500/4885CYP2D6 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.